TP53 and Thrombocytopenia: Synthetic MDM2 antagonists are characterized by high affinity (nanomolar) for MDM2 and robust efficacy in p53 wild-type tumors, but they often induce dose-limiting hematological toxicities like thrombocytopenia, due to on-target p53 activation in the bone marrow [140].